| Name | Title | Contact Details |
|---|
Cytrellis is a medical technology company dedicated to the development and commercialization of first-in-class aesthetic devices which emphasize safety, efficacy, and improved quality of life for our patients. Cytrellis` first product, the ellacor® System with Micro-Coring™ Technology, is indicated for use by medical professionals for the treatment of moderate to severe wrinkles in the mid to lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV. Ellacor provides aesthetic practitioners with an unprecedented ability to improve age-related changes in skin and to help restore youthful beauty.
Ossio is an orthopedic medical device company founded in Israel in 2014 with the vision to completely transform the orthopedic experience for physicians, patients, and payors. Ossio`s mission is to replace metal implants as the standard of care in the $10B+ orthopedic fixation market (screws, pins, plates) with an intelligent bone regeneration technology.
Hospicelink has created a nationally recognized , award winning software solution, specifically focused on the unique relationship between Hospice Companies and DME Providers. Although the needs of each Company can be vastly different, we understand the pressures in today`s marketplace and the difficulties these create for the industry. Hospicelink has addressed the challenges of providing optimal care while maintaining compliance and improving operational efficiencies, enabling your staff to balance multiple responsibilities. Hospicelink has a proven track record of helping clients solve these problems through our comprehensive set of innovative solutions. Our state-of-the-art application assists Hospice Companies and DME Providers with the ordering, billing, reporting and contract management processes. Hospicelink`s Executive Dashboard provides access to real-time actionable data, allowing a proactive response and improvement of identified inefficiencies.
IDEX Health & Science is the global authority in fluidics and optics` bringing life to advanced optofluidic technologies with our products` people and engineering expertise. We are respected worldwide for solving complex problems and delivering complete path innovation for analytical` diagnostic and biotechnology applications for the life sciences market. As a genuine and trustworthy partner` we solve our customers’ most demanding challenges with the industry`s most extensive portfolio of state-of-the-art components and capabilities that are unrivaled in breadth` quality` performance and design. Our vision of the complete path goes far beyond just meeting our customers’ needs — it anticipates them` with intelligent solutions for life.
VeriTeQ's core technology evolved from implantable radio frequency identification (RFID) microchip technology used in the health care community for over two decades. This first-of-its-kind implantable RFID technology was cleared for use by the FDA in 2004 as a Class II medical device, originally to identify at-risk patients at the point of care. It has now evolved to help medical device manufacturers meet mandatory regulations outlined in the FDA's Safety & Innovation Act, signed into law in July 2012, and the FDA's Unique Device Identification (UDI) Final Rule. This technology is VeriTeQ's Q Inside Safety Technology. VeriTeQ's dosimeter technologies are used in the oncology suite and give an oncology team the ability to measure the dosage of radiation delivered to a patient on a per treatment basis. The data collected from our dosimeter technologies is invaluable when recording the total amount of radiation that a patient is exposed to during the entire treatment regimen, and the data can be used on a generic basis to develop future treatment regimens and evidence-based healthcare. VeriTeQ is developing an informatics and data analytics platform that will improve the type of medical device and treatment regimen data that can be used in many applications to improve patient healthcare and outcomes. Such examples include using VeriTeQ's UDI data in supply chain management for medical device manufacturers and healthcare institutions, quality and reimbursement controls for hospitals, and treatment regimen data for patients receiving chemotherapy and radiation therapy. VeriTeQ owns a rich portfolio of intellectual property protecting all of its current and future technologies.